TEK and neoplasm: Clinical studies testing ANG-2/angiopoietin-1/TIE2 inhibition with various substances failed to mirror the promising preclinical results which is presumably due to the complex context-dependent impact of the angiopoietin/TIE2 axis on the endothelium and other tumor stromal cells such as myeloid derived cells (30).